Marimed INC

MariMed Inc. announced the results of its 2026 Annual Meeting of Stockholders, where four directors were re-elected and the appointment of M&K CPAs PLLC as independent auditors was approved on an advisory basis.

MariMed reports Q1 2026 revenue of $39.5 million, reflecting year-over-year growth and improved operational profitability.

MariMed Inc. has restructured a $14.2 million obligation to Navy Capital, converting it into $8 million in new promissory notes and 26.9 million shares of new convertible preferred stock.

MariMed Inc. reported a slight revenue increase to $40.8 million in Q3 2025, alongside a widened GAAP net loss of $2.9 million, while expanding its brand distribution.

MariMed Inc. reported mixed financial results for Q2 2025, with sequential revenue growth and increased Adjusted EBITDA, but year-over-year declines in revenue and gross margin, alongside strategic expansion into new markets.

MariMed Inc. announced that its stockholders re-elected four directors and approved the appointment of M&K CPAs PLLC as independent auditors for the 2025 fiscal year at its Annual Meeting held on June 12, 2025.

MariMed Inc. reported a 4.2% increase in revenue for Q1 2026, reaching $39.5 million, while net loss attributable to common stockholders narrowed to $3.8 million.

MariMed Inc. reported a significant net loss in the third quarter of 2025 despite slight revenue growth, as it navigates strategic market exits and a substantial IRS tax liability.

MariMed Inc. reported a slight revenue decrease and a wider net loss for H1 2025, alongside an IRS tax lien and OTCQX listing compliance concerns.

MariMed Inc. reports flat revenue for Q1 2025 with a net loss, impacted by acquisition-related expenses and a bad debt expense.

MariMed Inc. reports a 4.6% increase in revenue for the third quarter of 2024 compared to the same period last year, driven by wholesale growth.

MariMed Inc. saw a 10.7% increase in revenue year-over-year in the second quarter of 2024, driven by wholesale growth, while also reporting a net loss.

MariMed Inc. reports a 1.3% revenue increase in 2025, driven by wholesale growth and strategic acquisitions, while navigating evolving cannabis regulations and federal tax challenges.

MariMed Inc. announces a 6.3% increase in revenue for fiscal year 2024, driven by wholesale growth and strategic acquisitions, including the completion of the FSCC acquisition.

MariMed Inc. reports a 10.9% increase in total revenue for 2023, driven by growth in product sales, despite challenges in other revenue streams.

Jon R Levine, President and CEO, a Director and 10% owner of Marimed Inc., reported multiple transactions in common stock on July 15, 2026.

Timothy Shaw, Chief Operating Officer of Marimed Inc., reported multiple transactions in common stock on July 15, 2026.

Ryan Crandall, Chief Commercial Officer of Marimed Inc., reported multiple transactions in common stock on July 15, 2026.

Mario Pinho, Chief Financial Officer of Marimed Inc., reported multiple transactions in common stock on July 15, 2026.

Eva M.D. Selhub, a Director of Marimed Inc., reported multiple transactions in common stock on July 15, 2026.

David R Allen, a Director of Marimed Inc., reported multiple transactions in common stock on July 15, 2026.

MariMed Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 4, 2026, to elect directors and approve auditors.

MariMed Inc. has announced its 2025 Annual Meeting of Stockholders to be held on June 12, 2025, including proposals for the election of directors and the advisory approval of independent auditors.

MariMed Inc. has scheduled its 2024 Annual Meeting of Stockholders for June 6, 2024, to elect directors and approve the appointment of independent auditors.